Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

SYNC184322C

Synthware™ chromatography column with PTFE stopcock and coarse fritted disc

top joint: ST/NS 24/40, I.D. × L 26.0 mm × 254 mm

Synonym(s):

Synthware C184322C, glass chromatograpy column

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41121800
NACRES:
NB.51
Pricing and availability is not currently available.

joint

joint: ST/NS top24/40

packaging

pkg of 1 ea

manufacturer/tradename

Synthware C184322C

I.D. × L

26.0 mm × 254 mm

suitability

suitable for chromatography

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
EHU015981EMU003391EMU005061
MISSION® esiRNA targeting mouse Cdc42ep2

EMU007361

MISSION® esiRNA

MISSION® esiRNA targeting human CDC42EP2

EHU015981

MISSION® esiRNA

MISSION® esiRNA targeting mouse Arap3

EMU003391

MISSION® esiRNA

MISSION® esiRNA targeting mouse Acly

EMU005061

MISSION® esiRNA

esiRNA cDNA target sequence

CAGCTCTCCAAAGGGACTTGCATCCATCTAGAAGAGAGGAGGGTGTATTCACCACCCTGTCTTTGTTGGCCTTTAATCTAACTTTACCTGACACCTTGGGCCAACTTTGATCACATCTCACCCTCTACTTTTGTTTTGTTTTTGGCAAGAGTGGACATTGGCCCTCTGGAGCCTGTTTTGGGCAGAGGGTGTTGAGAGAGTACTGAGGACTGAGCGGCCAGGACTGTGTGCTGAAGTCACCATGTCCACCAAGGTCCCCATCTATTTGAAACGTGGCAGCCGCAAAGGCAAGAAAGAGAAGCTTCGGGACCTGCTGTCCTCAGACATGATCAGCCCACCACTTGGGGACTTCCGTCACACTATTCACATTGGCAGCGGTGGCGGAGATGACATGTTTGGGGACATCTCCTTC

esiRNA cDNA target sequence

TCAGAAGAGTTTGCCGTCCTTTGGGGAGAACGTGATTTTTGTTATCTCAGCCCACTGACTTCATTGATCTCTAATCTTTTTTAATTCCTTGGGCCAACTTTGTTCGTGCCCCCACACTGTAGCCAGAAGCCCGTTGGCGAGCTCTGGCACCTGCAAACCACCCCGTGGAACGAGTGTTTCCTCTGGCTGAGGGTTGGAGAGGAGGTGTGGTCTCAGCAGGCGGCCCGTAGCCTCACAGCCAGGCCTGGTGGTGAGGTCACCATGTCCACCAAGGTGCCCATCTATCTGAAGCGTGGCAGTCGCAAGGGCAAGAAGGAGAAGCTTCGGGACCTGCTGTCCTCGGACATGATCAGCCCACCGCTGGGGGACTTCCGCCACACCATTCATATTGGCAGTGGCGGCGGCAGTGACATGTTTGGCGACATC

esiRNA cDNA target sequence

GCGCCTGGAGAAGTACAAAGAAGTGATTAGCTGCCTGCCTCGAGTCAACCGCAGAACACTGGCCACCCTCATCGGGCATCTGTACCGGGTGCAGAAGTGTGCGTCTCTAAACCAGATGTGCACGCGGAACCTGGCCCTACTGTTTGCACCTAGTGTGTTCCAGACAGATGGGCGGGGAGAGCATGAGGTTCGGGTACTGCAGGAGCTCATCGATGGCTACATCTCTGTTTTTGATATTGACTCGGACCAGGCAGCTCAGATTGACTTGGAGGTCAGTCTCATTACCACCTGGAAGGATGTGCAGTTGTCCCAGGCTGGAGACCTCATCATGGAGGTTTACATAGAACAGCAGCTCCCGGACAACTGTGTCACCCTAAAGGTATCCCCAACACTGACTGCTGAGGA

esiRNA cDNA target sequence

CATCGGCCATCGAGTAAAATCGATAAACAACCCAGACATGCGAGTGCAGATCCTCAAGGACTTCGTCAAACAGCACTTCCCCGCCACCCCGCTGCTCGACTATGCCCTGGAAGTGGAGAAGATTACCACCTCCAAGAAGCCAAATCTTATCCTGAATGTGGACGGCTTCATCGGCGTTGCGTTTGTGGACATGCTCAGGAACTGTGGCTCCTTCACCCGGGAGGAAGCTGATGAATATGTTGACATTGGAGCCCTCAATGGCATCTTTGTGCTAGGAAGGAGTATGGGCTTCATTGGGCACTACCTTGACCAGAAGAGGCTGAAGCAAGGGCTGTATCGTCACCCCTGGGATGACATTTCCTATGTTCTTCCAGAACACATGAGCATGTAACTGAGCCAGGAGCCCTA

Gene Information

mouse ... CDC42EP2(104252), Cdc42ep2(104252)

Gene Information

human ... CDC42EP2(10435), CDC42EP2(10435)

Gene Information

mouse ... ARAP3(106952), Arap3(106952)

Gene Information

mouse ... ACLY(104112), Acly(104112)

Ensembl | mouse accession no.

ENSMUSG00000045664

Ensembl | mouse accession no.

-

Ensembl | mouse accession no.

ENSMUSG00000024451

Ensembl | mouse accession no.

ENSMUSG00000020917

product line

MISSION®

product line

MISSION®

product line

MISSION®

product line

MISSION®

form

lyophilized powder

form

lyophilized powder

form

lyophilized powder

form

lyophilized powder

NCBI accession no.

NM_026772

NCBI accession no.

NM_006779

NCBI accession no.

NM_139206

NCBI accession no.

NM_134037

General description

General purpose column has a PTFE stopcock and a top outer joint. With a coarse porosity fritted disc to support column packing. The section below disc is carefully minimized to prevent re-mixing of components already separated. All Synthware columns are heavy wall designed to increase safety.
This product includes coarse fritted disc.

Legal Information

Synthware is a trademark of Kemtech America Inc.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rong Chen et al.
Biochemistry, 57(18), 2704-2710 (2018-04-14)
Molecular dynamics simulations are employed to determine the inhibitory mechanisms of three drugs, 5-(4-phenoxybutoxy)psoralen (PAP-1), vernakalant, and flecainide, on the voltage-gated K+ channel Kv1.5, a target for the treatment of cardiac arrhythmia. At neutral pH, PAP-1 is neutral, whereas the
Jonas Goldin Diness et al.
Circulation. Arrhythmia and electrophysiology, 10(10) (2017-10-12)
Evidence has emerged that small-conductance Ca2+-activated K+ (SK) channels constitute a new target for treatment of atrial fibrillation (AF). SK channels are predominantly expressed in the atria as compared with the ventricles. Various marketed antiarrhythmic drugs are limited by ventricular
Gerrit Frommeyer et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 19(5), 866-873 (2016-10-06)
The antiarrhythmic drug vernakalant exerts antiarrhythmic effects in atrial fibrillation. Recent experimental data suggest interactions with the late sodium current and antiarrhythmic effects in ventricular arrhythmias. We aimed at investigating whether treatment with vernakalant reduces polymorphic ventricular tachycardia (VT) in
Toshiki Chiba et al.
Journal of pharmacological sciences, 130(3), 170-176 (2016-04-02)
Electrical remodeling plays a pivotal role in maintaining the reentry during atrial fibrillation. In this study, we assessed influence of electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits. We used an atrial electrical remodeling model of the
Gerrit Frommeyer et al.
Journal of cardiovascular medicine (Hagerstown, Md.), 18(9), 663-668 (2017-07-12)
Current guidelines recommend vernakalant for pharmacologic cardioversion of recent-onset atrial fibrillation. However, this drug is not established as chronic therapy. In total, 15 rabbit hearts were Langendorff-perfused. A burst pacing protocol-induced atrial fibrillation in 7 of 15 hearts at baseline

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service